Investigational New Drug

Definition

An Investigational New Drug (IND) application is an FDA regulatory submission required before a new drug or biologic can be administered to human subjects in clinical research in the United States. The IND application includes preclinical data (animal toxicology and pharmacology studies), manufacturing information (composition, manufacturer, stability), and a clinical investigation plan (protocol, investigator qualifications, informed consent documents). FDA reviews IND applications to determine whether there is sufficient preclinical evidence to allow initiation of the proposed human studies with acceptable safety risk. An effective IND allows the sponsor to ship the investigational compound across state lines for clinical use.

Research Context

The IND framework is relevant to understanding the regulatory pathway from preclinical research compound to clinical investigation. Research-grade peptides sold for in vitro research use occupy the preclinical stage of this continuum and would require an IND submission, supported by substantial preclinical data packages, before any human clinical research could be initiated. Understanding this regulatory pathway helps researchers contextualize where their in vitro and preclinical research fits in the broader drug development landscape and what additional steps would be required to advance a promising research compound toward clinical evaluation.